Therapeutic benefits of combined treatment with tissue plasminogen activator and 2-(4-methoxyphenyl)ethyl-2-acetamido-2-deoxy-β-d-pyranoside in an animal model of ischemic stroke

Neuroscience

Volumn 327, Issue , 2016, Pages 44-52

  Yu, Shu ^a   Liu, Xin ^a   Shen, Yuntian ^a   Xu, Hui ^a   Yang, Yumin ^a   Ding, Fei ^a  

^a NANTONG UNIVERSITY   (China)

Author keywords

2 (4 methoxyphenyl)ethyl 2 acetamido 2 deoxy d pyranoside; Ischemic stroke; Neuroprotection; Thrombolytic therapy; Tissue plasminogen activator

Indexed keywords

2 (4 METHOXYPHENYL)ETHYL 2 ACETAMIDO 2 DEOXY BETA DEXTRO PYRANOSIDE; SALIDROSIDE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; 2-(4-METHOXYPHENYL)ETHYL-2-ACETAMIDO-2-DEOXYGLUCOPYRANOSIDE; FIBRINOLYTIC AGENT; N ACETYLGLUCOSAMINE; NEUROPROTECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD CLOT LYSIS; BODY EQUILIBRIUM; BRAIN DYSFUNCTION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN ISCHEMIA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FIBRINOLYTIC THERAPY; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MIDDLE CEREBRAL ARTERY; MIDDLE CEREBRAL ARTERY OCCLUSION; MODIFIED NEUROLOGICAL SEVERITY SCORE; MOTOR ACTIVITY; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; REFLEX; SCORING SYSTEM; SENSORY FEEDBACK; SPRAGUE DAWLEY RAT; SURVIVAL RATE; TUNEL ASSAY; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CEREBRAL ARTERY DISEASE; CEREBRAL HEMORRHAGE; COMPLICATION; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; MULTIMODALITY CANCER THERAPY; PROCEDURES; STROKE;

ACETYLGLUCOSAMINE; ANIMALS; BRAIN; CEREBRAL HEMORRHAGE; COMBINED MODALITY THERAPY; DISEASE MODELS, ANIMAL; FIBRINOLYTIC AGENTS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; NEUROPROTECTIVE AGENTS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84964326619     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2016.04.006     Document Type: Article

References (39)

1. Campbell B.C., Meretoja A., Donnan G.A., Davis S.M. Twenty-year history of the evolution of stroke thrombolysis with intravenous alteplase to reduce long-term disability. Stroke 2015, 46:2341-2346.
2. Cao L.L., Du G.H., Wang M.W. The effect of salidroside on cell damage induced by glutamate and intracellular free calcium in PC12 cells. J Asian Nat Prod Res 2006, 8:159-165.
3. Carpenter C.R., Keim S.M., Milne W.K., Meurer W.J., Barsan W.G. Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med 2011, 40:82-92.
4. Cesarman-Maus G., Hajjar K.A. Molecular mechanisms of fibrinolysis. Br J Haematol 2005, 129:307-321.
5. Chen J., Li Y., Wang L., Zhang Z., Lu D., Lu M., Chopp M. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke 2001, 32:1005-1011.
6. Chen X., Zhang Q., Cheng Q., Ding F. Protective effect of salidroside against H2O2-induced cell apoptosis in primary culture of rat hippocampal neurons. Mol Cell Biochem 2009, 332:85-93.
7. Chiu D., Krieger D., Villar-Cordova C., Kasner S.E., Morgenstern L.B., Bratina P.L., Yatsu F.M., Grotta J.C. Intravenous tissue plasminogen activator for acute ischemic stroke: feasibility, safety, and efficacy in the first year of clinical practice. Stroke 1998, 29:18-22.
8. Collen D. The plasminogen (fibrinolytic) system. Thromb Haemost 1999, 82:259-270.
9. Dijkhuizen R.M., Asahi M., Wu O., Rosen B.R., Lo E.H. Rapid breakdown of microvascular barriers and subsequent hemorrhagic transformation after delayed recombinant tissue plasminogen activator treatment in a rat embolic stroke model. Stroke 2002, 33:2100-2104.
10. Dinapoli V.A., Rosen C.L., Nagamine T., Crocco T. Selective MCA occlusion: a precise embolic stroke model. J Neurosci Methods 2006, 154:233-238.
11. Gross J.L., Moscatelli D., Jaffe E.A., Rifkin D.B. Plasminogen activator and collagenase production by cultured capillary endothelial cells. J Cell Biol 1982, 95:974-981.
12. Gubern C., Hurtado O., Rodriguez R., Morales J.R., Romera V.G., Moro M.A., Lizasoain I., Serena J., Mallolas J. Validation of housekeeping genes for quantitative real-time PCR in in-vivo and in-vitro models of cerebral ischaemia. BMC Mol Biol 2009, 10:57.
13. Guo Y., Zhao Y., Zheng C., Meng Y., Yang Y. Synthesis, biological activity of salidroside and its analogues. Chem Pharm Bull (Tokyo) 2010, 58:1627-1629.
14. Hacke W., Kaste M., Bluhmki E., Brozman M., Davalos A., Guidetti D., Larrue V., Lees K.R., Medeghri Z., Machnig T., Schneider D., von Kummer R., Wahlgren N., Toni D. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008, 359:1317-1329.
15. Hatcher M.A., Starr J.A. Role of tissue plasminogen activator in acute ischemic stroke. Ann Pharmacother 2010, 45:364-371.
16. Hofmeijer J., van Putten M.J. Ischemic cerebral damage: an appraisal of synaptic failure. Stroke 2012, 43:607-615.
17. Huang J., Li Y., Tang Y., Tang G., Yang G.Y., Wang Y. CXCR4 antagonist AMD3100 protects blood-brain barrier integrity and reduces inflammatory response after focal ischemia in mice. Stroke 2013, 44:190-197.
18. Hwang S.Y., Shin J.H., Hwang J.S., Kim S.Y., Shin J.A., Oh E.S., Oh S., Kim J.B., Lee J.K., Han I.O. Glucosamine exerts a neuroprotective effect via suppression of inflammation in rat brain ischemia/reperfusion injury. Glia 2010, 58:1881-1892.
19. Jin R., Zhu X., Li G. Embolic middle cerebral artery occlusion (MCAO) for ischemic stroke with homologous blood clots in rats. J Vis Exp 2014, 10.3791/51956.
20. Joshi C.N., Jain S.K., Murthy P.S. An optimized triphenyltetrazolium chloride method for identification of cerebral infarcts. Brain Res Brain Res Protoc 2004, 13:11-17.
21. Kawamura K., Takahashi T., Kanazawa M., Igarashi H., Nakada T., Nishizawa M., Shimohata T. Effects of angiopoietin-1 on hemorrhagic transformation and cerebral edema after tissue plasminogen activator treatment for ischemic stroke in rats. PLoS ONE 2014, 9:e98639.
22. Khan M., Im Y.B., Shunmugavel A., Gilg A.G., Dhindsa R.K., Singh A.K., Singh I. Administration of S-nitrosoglutathione after traumatic brain injury protects the neurovascular unit and reduces secondary injury in a rat model of controlled cortical impact. J Neuroinflammation 2009, 6:32.
23. Lees K.R., Bluhmki E., von Kummer R., Brott T.G., Toni D., Grotta J.C., Albers G.W., Kaste M., Marler J.R., Hamilton S.A., Tilley B.C., Davis S.M., Donnan G.A., Hacke W., Allen K., Mau J., Meier D., del Zoppo G., De Silva D.A., Butcher K.S., Parsons M.W., Barber P.A., Levi C., Bladin C., Byrnes G. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet 2010, 375:1695-1703.
24. Liu D., Cheng T., Guo H., Fernandez J.A., Griffin J.H., Song X., Zlokovic B.V. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med 2004, 10:1379-1383.
25. Liu R., Liu Q., He S., Simpkins J.W., Yang S.H. Combination therapy of 17beta-estradiol and recombinant tissue plasminogen activator for experimental ischemic stroke. J Pharmacol Exp Ther 2010, 332:1006-1012.
26. Macrez R., Obiang P., Gauberti M., Roussel B., Baron A., Parcq J., Casse F., Hommet Y., Orset C., Agin V., Bezin L., Berrocoso T.G., Petersen K.U., Montaner J., Maubert E., Vivien D., Ali C. Antibodies preventing the interaction of tissue-type plasminogen activator with N-methyl-d-aspartate receptors reduce stroke damages and extend the therapeutic window of thrombolysis. Stroke 2011, 42:2315-2322.
27. Meng Y., Guo Y., Ling Y., Zhao Y., Zhang Q., Zhou X., Ding F., Yang Y. Synthesis and protective effects of aralkyl alcoholic 2-acetamido-2-deoxy-beta-d-pyranosides on hypoglycemia and serum limitation induced apoptosis in PC12 cell. Bioorg Med Chem 2011, 19:5577-5584.
28. Otwell J.L., Phillippe H.M., Dixon K.S. Efficacy and safety of i.v. alteplase therapy up to 4.5 hours after acute ischemic stroke onset. Am J Health Syst Pharm 2010, 67:1070-1074.
29. Syrovets T., Lunov O., Simmet T. Plasmin as a proinflammatory cell activator. J Leukoc Biol 2012, 92:509-519.
30. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333:1581-1587. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
31. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28:2109-2118. The NINDS t-PA Stroke Study Group.
32. Tsuji K., Aoki T., Tejima E., Arai K., Lee S.R., Atochin D.N., Huang P.L., Wang X., Montaner J., Lo E.H. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36:1954-1959.
33. Wang Y.F., Tsirka S.E., Strickland S., Stieg P.E., Soriano S.G., Lipton S.A. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998, 4:228-231.
34. Wang Y., Zhang Z., Chow N., Davis T.P., Griffin J.H., Chopp M., Zlokovic B.V. An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents. Stroke 2012, 43:2444-2449.
35. Wu F., Wu J., Nicholson A.D., Echeverry R., Haile W.B., Catano M., An J., Lee A.K., Duong D., Dammer E.B., Seyfried N.T., Tong F.C., Votaw J.R., Medcalf R.L., Yepes M. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci 2012, 32:9848-9858.
36. Yu S., Liu M., Gu X., Ding F. Neuroprotective effects of salidroside in the PC12 cell model exposed to hypoglycemia and serum limitation. Cell Mol Neurobiol 2008, 28:1067-1078.
37. Yu S., Cheng Q., Li L., Liu M., Yang Y., Ding F. 2-(4-Methoxyphenyl)ethyl-2-acetamido-2-deoxy-beta-d-pyranoside confers neuroprotection in cell and animal models of ischemic stroke through calpain1/PKA/CREB-mediated induction of neuronal glucose transporter 3. Toxicol Appl Pharmacol 2014, 277:259-269.
38. Zhang R.L., Chopp M., Zhang Z.G., Jiang Q., Ewing J.R. A rat model of focal embolic cerebral ischemia. Brain Res 1997, 766:83-92.
39. Zhang S., Chen X., Yang Y., Zhou X., Liu J., Ding F. Neuroprotection against cobalt chloride-induced cell apoptosis of primary cultured cortical neurons by salidroside. Mol Cell Biochem 2011, 354:161-170.